Meteora Capital’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $165K | Hold |
2,755,935
| – | – | 0.01% | 243 |
|
|
2026
Q1 | $193K | Hold |
2,755,935
| – | – | 0.01% | 196 |
|
|
2025
Q4 | $138K | Hold |
2,755,935
| – | – | 0.01% | 212 |
|
|
2025
Q3 | $303K | Buy |
+2,755,935
| New | +$303K | 0.03% | 148 |
|
|
2025
Q1 | – | Sell |
-2,772,145
| Closed | -$1.82M | – | 186 |
|
|
2024
Q4 | $1.82M | Buy |
2,772,145
+1,887,400
| +213% | +$769K | 0.6% | 46 |
|
|
2024
Q3 | $334K | Sell |
884,745
-283,245
| -24% | -$251K | 0.09% | 109 |
|
|
2024
Q2 | $1.48M | Sell |
1,167,990
-39,626
| -3% | -$55.4K | 0.27% | 91 |
|
|
2024
Q1 | $2.28M | Sell |
1,207,616
-389,201
| -24% | -$747K | 0.39% | 66 |
|
|
2023
Q4 | $4.39M | Sell |
1,596,817
-525,898
| -25% | -$1.7M | 0.75% | 34 |
|
|
2023
Q3 | $17.6M | Buy |
2,122,715
+2,067,811
| +3,766% | +$21M | 3% | 4 |
|
|
2023
Q2 | $567K | Buy |
54,904
+309
| +0.6% | +$3.16K | 0.1% | 157 |
|
|
2023
Q1 | $553K | Buy |
54,595
+34,746
| +175% | +$351K | 0.07% | 186 |
|
|
2022
Q4 | $197K | Sell |
19,849
-14,897
| -43% | -$147K | 0.04% | 174 |
|
|
2022
Q3 | $339K | Buy |
+34,746
| New | +$339K | 0.09% | 166 |
|
Meteora Capital's NKGN Position: Q2 2026 in Review
Meteora Capital held its NKGen Biotech, Inc. Common Stock (NKGN) position steady in Q2 2026 at 2,755,935 shares worth $165K. The position accounts for 0.01% of the portfolio, ranked #243.
Meteora Capital first reported a position in NKGN in Q3 2022 and has held it in 14 quarters since. The position peaked at $17.6M in Q3 2023. 1 fund tracked by Wall St. Rank holds NKGN as of Q2 2026.
- Meteora Capital held 2,755,935 shares of NKGen Biotech, Inc. Common Stock worth $165K as of Q2 2026.
- Meteora Capital left its NKGen Biotech, Inc. Common Stock share count unchanged in Q2 2026.
- NKGen Biotech, Inc. Common Stock made up 0.01% of Meteora Capital's portfolio in Q2 2026, its #243 holding.
- Meteora Capital first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and has held it in 14 quarters since.
- Meteora Capital's NKGen Biotech, Inc. Common Stock position peaked at $17.6M in Q3 2023.
- 1 fund tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2026.
Based on Meteora Capital's 13F filing for Q2 2026, filed 14 Aug 2026.